

19 August 2025

Oncology Treatments

1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

Staging not available. Please see below figures encompassing all NSCLC SACT.

- **Atezolizumab (Tecentriq):** <5.
- **Durvalumab (Imfinzi):** <5.
- **Nivolumab (Opdivo):** <5.
- **Pembrolizumab (Keytruda):** 9.
- **Chemotherapy:** Afatinib <5, Alectinib 5, CisplatinVinorelbine <5, Crizotinib <5, Gemcitabine Carboplatin <5, Osimertinib 9, Osimertinib Pemetrexed Carboplatin <5, Paclitaxel Carboplatin <5, Pemetrexed Carboplatin <5, Pembrolizumab Carboplatin <5, Pembrolizumab Paclitaxel Carboplatin <5, Pembrolizumab Pemetrexed Carboplatin 7.
- **Radiotherapy:** In the 3 months April, May and June 2025 there were 40 patients referred for NSCLC. We do not have information regarding stage and non-metastatic as we do not capture this on our radiotherapy referral or in Aria.
- **Chemotherapy AND Radiotherapy:** Carboplatin Vinorelbine XRT 5, Paclitaxel Carboplatin XRT 8.
- **Osimertinib:** 9.

2. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?

All Stages Melanoma 48.

3. How many patients has your Trust treated in total in the past 3 months for:

- **Stage 2 Non-Small Cell Lung Cancer**
- **Stage 3 Non-Small Cell Lung Cancer**

All stages NSCLC 61.

4. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- **Atezolizumab**
- **Pembrolizumab monotherapy**
- **Pembrolizumab with chemotherapy**
- **Nivolumab**
- **Osimertinib**

19 August 2025

- **Durvalumab**
- **Chemotherapy**
- **Radiotherapy**
- **Chemotherapy and Radiotherapy**

As above.

5. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months following surgery with:

- **Chemotherapy**
- **Radiotherapy**
- **Chemotherapy + Radiotherapy**

As above.

6. How many Stage 2-3 resectable non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- **Durvalumab**

As above.

N.B. Use of less than five (<5) - We are not able to provide the information requested. The low numbers involved would reduce numbers to discoverable limits and, as a result, we consider that individuals could be identified and disclosure of this information would breach the first data protection principle, which relates to the fair and lawful processing of personal data. Therefore, we have concluded that this information is exempt from disclosure under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party.